PharmaMar
The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticancer agents in adult participants with advanced solid tumors. The study will also assess the antitumor activity of PM54 in combination with cytotoxic and targeted anticancer agents in terms of objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
The main study will comprise several sub-studies evaluating PM54 in combination with different anticancer agents, starting with the following combinations: PM54 plus irinotecan and PM54 plus doxorubicin. Each sub-study includes Part 1 (Dose Escalation) and Part 2 (Dose Expansion). In Part 1, participants with advanced malignancies of selected tumor types will receive escalated doses of PM54 in combination with the relevant anticancer agent until a suitable dose is established, or until clinical or objective disease progression, withdrawal of consent, or unacceptable or cumulative toxicity occ…
Inclusion Criteria: * Voluntarily signed and dated written informed consent, obtained before the start of any study-specific procedures. * Adults greater than or equal to (\>=) 18 years and able to provide free and informed consent for study participation. * Have a pathologically confirmed diagnosis of 1 of the following (Tumor types have been omitted, as this information is not public.): Sub- study 1 1. Tumor type, previously treated with 1 to 2 prior lines of therapy for advanced disease, which must have included at least 1 line of platinumbased chemotherapy and programmed cell death prot…
Intravenous infusion.
Intravenous infusion.
Intravenous infusion.